Share This Author
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
A multidisciplinary Toxicity Management Working Group met for a full-day workshop to develop recommendations to standardize management of immune-related adverse events, and presents their consensus recommendations on managing toxicities associated with immune checkpoint inhibitor therapy.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
- P. Kantoff, T. Schuetz, W. Godfrey
- MedicineJournal of clinical oncology : official journal…
- 1 March 2010
PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC, providing preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study.
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
The ability of avelumab to lyse a range of human tumor cells in the presence of PBMC or NK effectors is demonstrated and IFNγ can enhance tumor cell PD-L1 expression and, in some cases, enhance ADCC tumor cell lysis.
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
This vaccine regimen can be safely given in patients undergoing radiation therapy for localized prostate cancer, with the majority of patients generating a PSA-specific cellular immune response to vaccine.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
Evidence is provided that patients with more indolent mCRPC (Halabi predicted survival ≥18 months) may best benefit from vaccine therapy, and treg suppressive function was shown to decrease following vaccine in patients surviving longer than predicted, and increase in patients survive less than predicted.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents
It is suggested that anti-angiogenic and chemotherapy agents can predispose to the development of ONJ in men with mCRPC on zoledronic acid in chemotherapy-naïve men with metastatic castration resistant prostate cancer.
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
- Y. Ning, J. Gulley, W. Dahut
- Medicine, BiologyJournal of clinical oncology : official journal…
- 20 April 2010
The addition of bevacizumab and thalidomide to docetaxel is a highly active combination with manageable toxicities, and the estimated median survival is encouraging, given the generally poor prognosis of this patient population.
Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.
Safety and clinical activity of avelumab in patients (pts) with recurrent/refractory ovarian cancer with advanced OC unselected for PD-L1 expression is reported.